Bank of New York Mellon Corp reduced its stake in shares of Agenus Inc (NASDAQ:AGEN) by 11.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 405,768 shares of the biotechnology company’s stock after selling 51,722 shares during the quarter. Bank of New York Mellon Corp’s holdings in Agenus were worth $1,790,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. OxFORD Asset Management LLP acquired a new position in Agenus during the second quarter worth about $141,000. Voya Investment Management LLC grew its position in Agenus by 18.5% during the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,381 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Agenus in the second quarter valued at about $207,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Agenus by 6.7% in the second quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 4,006 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new stake in shares of Agenus in the second quarter valued at about $251,000. Institutional investors own 37.87% of the company’s stock.
Shares of Agenus Inc (NASDAQ:AGEN) opened at $3.89 on Wednesday. Agenus Inc has a fifty-two week low of $3.20 and a fifty-two week high of $5.45. The stock has a market cap of $338.43, a PE ratio of -3.32 and a beta of 2.11. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55.
Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Tuesday. BidaskClub downgraded shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 3rd. Finally, ValuEngine downgraded shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $5.88.
In related news, insider Karen Valentine sold 8,358 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $3.46, for a total transaction of $28,918.68. Following the transaction, the insider now owns 109,879 shares of the company’s stock, valued at $380,181.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Garo H. Armen acquired 100,000 shares of Agenus stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average cost of $3.55 per share, for a total transaction of $355,000.00. The disclosure for this purchase can be found here. Insiders sold 20,514 shares of company stock worth $70,978 in the last ninety days. Insiders own 7.90% of the company’s stock.
WARNING: “Agenus Inc (AGEN) Holdings Trimmed by Bank of New York Mellon Corp” was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/01/10/agenus-inc-agen-holdings-trimmed-by-bank-of-new-york-mellon-corp.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc (NASDAQ:AGEN).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.